Monopar Therapeutics stock price forecast: $66.1636 resistance in focus as MNPR climbs 3.12%
Monopar Therapeutics Inc. (MNPR) stock is trading at $63.3900, marking a daily gain of 3.12%. The price sits above its key short- and medium-term moving averages, reflecting a strong intraday upswing.
63.3900
61.7600
Highlights
- MNPR/USD demonstrates strong short- and medium-term bullish momentum, but faces significant long-term resistance above current levels.
- Most technical oscillators are overbought, signaling robust buyer pressure but increasing risk of a short-term pullback.
- Price is projected to consolidate between $61.7129 and $65.0671 over the next few sessions, with upside probability dominant.
Bullish momentum persists as overbought signals caution for reversal
MNPR has crossed above its MA-20 at $60.7557 and MA-50 at $60.2433, while remaining below long-term resistance at the MA-200 of $66.1636. The Ichimoku Kijun at $60.6300 is acting as immediate support. RSI stands at 64.73, MACD is on Buy, and Awesome Oscillator also signals upward movement, indicating bullish momentum. However, Stoch RSI, CCI, and BBP all register as Overbought, while ADX is Neutral, highlighting strong buyer pressure but a less decisive trend strength and increased potential for a short-term pullback.
Sideways consolidation projected as momentum challenges resistance
Over the next 2 to 3 trading days, MNPR is expected to fluctuate within a volatility band of $61.7129 to $65.0671. The baseline scenario calls for sideways consolidation within this corridor. Should bullish momentum persist, a breakout above resistance could drive further gains, while a drop below the Kijun level would risk initiating a corrective pullback.
In a recent review, analysts highlighted a bullish technical outlook for Monopar Therapeutics, while cautioning that sustained momentum would require confirmation above key longer-term resistance. With the latest session reinforcing upward pressure yet signaling potential for near-term exhaustion, traders should closely monitor for a decisive move beyond the current volatility band to signal the next directional trend.
Latest Monopar Therapeutics News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
